Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LJPC La Jolla Pharmaceutical (LJPC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About La Jolla Pharmaceutical Stock (NASDAQ:LJPC) 30 days 90 days 365 days Advanced Chart Ad True Gold RepublicCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. Get LJPC alerts:Sign Up Key Stats Today's Range N/A50-Day Range$3.12▼$6.2252-Week Range N/AVolume66,708 shsAverage Volume158,476 shsMarket Capitalization$155.11 millionP/E Ratio51.84Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewLa Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.Read More… Central Bank Abandons USD (Ad)Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. La Jolla Pharmaceutical Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks47th Percentile Overall ScoreLJPC MarketRank™: La Jolla Pharmaceutical scored higher than 47% of companies evaluated by MarketBeat, and ranked 595th out of 977 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for La Jolla Pharmaceutical. Earnings and Valuation3.1 / 5Proj. Earnings Growth475.00% Earnings GrowthEarnings for La Jolla Pharmaceutical are expected to grow by 475.00% in the coming year, from $0.04 to $0.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of La Jolla Pharmaceutical is 51.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.29.Price to Earnings Ratio vs. SectorThe P/E ratio of La Jolla Pharmaceutical is 51.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 136.31. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for LJPC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLa Jolla Pharmaceutical does not currently pay a dividend.Dividend GrowthLa Jolla Pharmaceutical does not have a long track record of dividend growth. Sustainability and ESG2.5 / 5Environmental Score-2.77 Short InterestThere is no current short interest data available for LJPC. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for La Jolla Pharmaceutical this week, compared to 0 articles on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, La Jolla Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by Insiders36.30% of the stock of La Jolla Pharmaceutical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.06% of the stock of La Jolla Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about La Jolla Pharmaceutical's insider trading history. Receive LJPC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address LJPC Stock News HeadlinesAurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of GrowthNovember 8, 2024 | theglobeandmail.comAurinia stock jumps 14% on Q3 earnings, restructuring announcementNovember 7, 2024 | msn.comCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. November 12, 2024 | True Gold Republic (Ad)Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024October 15, 2024 | finance.yahoo.comLongboard Pharmaceuticals Shares Hit All-Time High on Takeover by LundbeckOctober 14, 2024 | marketwatch.comH. Lundbeck to Buy Longboard Pharmaceuticals for $2.6 Billion -- UpdateOctober 14, 2024 | marketwatch.comInnoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company ProgressMay 8, 2024 | finance.yahoo.comLa Jolla small business owners want lawful path to conduct business on the beachMarch 27, 2024 | msn.comSee More Headlines LJPC Stock Analysis - Frequently Asked Questions How were La Jolla Pharmaceutical's earnings last quarter? La Jolla Pharmaceutical (NASDAQ:LJPC) posted its quarterly earnings data on Monday, May, 16th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.16. The biopharmaceutical company had revenue of $10.43 million for the quarter, compared to analysts' expectations of $13.10 million. La Jolla Pharmaceutical had a net margin of 8.54% and a negative trailing twelve-month return on equity of 5.46%. What other stocks do shareholders of La Jolla Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), El Pollo Loco (LOCO), Intercept Pharmaceuticals (ICPT), Bristol-Myers Squibb (BMY), Exelixis (EXEL), Sarepta Therapeutics (SRPT) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings5/16/2022Today11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LJPC CUSIPN/A CIK920465 Webwww.lajollapharmaceutical.com Phone(617) 715-3600Fax858-626-2851Employees61Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.12 Trailing P/E Ratio51.84 Forward P/E RatioN/A P/E GrowthN/ANet Income$19.66 million Net Margins8.54% Pretax Margin8.64% Return on Equity-5.46% Return on Assets4.00% Debt Debt-to-Equity RatioN/A Current Ratio4.02 Quick Ratio3.52 Sales & Book Value Annual Sales$75.72 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow7.95 Book Value($2.94) per share Price / BookN/AMiscellaneous Outstanding Shares24,937,000Free Float15,885,000Market Cap$155.11 million OptionableOptionable Beta2.39 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:LJPC) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | SponsoredCrypto’s FINAL Wealth MomentBitcoin’s final bull market is here. If you missed out on the gains in 2017, or 2021… 2025 stands to be jus...Paradigm Press | SponsoredWhy Trump’s Win Can’t Stop the Coming Crisis - Protect Yourself NowNo matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding La Jolla Pharmaceutical Please log in to your account or sign up in order to add this asset to your watchlist. Share La Jolla Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.